Clinical use of [¹⁸F]fluoro-ethyl-L-tyrosine PET co-registered with MRI for localizing prolactinoma remnants.

ABSTRACT:

Purpose

To assess the utility of [¹⁸F]fluoroethyl-L-tyrosine PET co-registered with magnetic resonance imaging ([¹⁸F]FET-PET/MRI^CR) in patients with difficult-to-localize prolactinoma to inform clinical decision-making and (surgical) treatment planning.

Methods

Retrospective cohort study of 17 consecutive patients with prolactinoma undergoing [¹⁸F]FET-PET/MRI^CR between October 2020 and September 2022 for either (1) additional information in case of difficult-to-visualize remnants after prior transsphenoidal surgery (TSS), or pharmacological treatment, or (2) radiological diagnosis in absence of a (clear) adenoma on diagnostic/post-treatment conventional MRI.

Results

[¹⁸F]FET-PET/MRI^CR identif

SUBMITTER: van Trigt VR 

PROVIDER: S-EPMC11513721 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature